Perspective: Does ranolazine have potential for the treatment of atrial fibrillation?

Expert Opinion on Investigational Drugs

Volumn 19, Issue 12, 2010, Pages 1465-1474

  Hancox, Jules C ^a   Doggrell, Sheila A ^b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

antiarrhythmic; atrial fibrillation; ranolazine

Indexed keywords

2 [7 [3 (4 CYANOPHENOXY) 2 HYDROXYPROPYL] 9 OXA 3,7 DIAZABICYCLO[3.3.1]NON 3 YL]ETHYLCARBAMIC ACID TERT BUTYL ESTER; AMIODARONE; AMLODIPINE; ANTIARRHYTHMIC AGENT; ATENOLOL; DILTIAZEM; DOFETILIDE; FLECAINIDE; GYKI 16638; POTASSIUM CHANNEL; RANOLAZINE; SODIUM CHANNEL; SOTALOL; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ANGINA PECTORIS; ANTIARRHYTHMIC ACTIVITY; ATRIOVENTRICULAR BLOCK; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG MEGADOSE; HEART ATRIUM ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ELECTROPHYSIOLOGY; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; IC 50; NONHUMAN; REVIEW; SINUS BRADYCARDIA; SINUS TACHYCARDIA; SUPRAVENTRICULAR TACHYCARDIA;

ACETANILIDES; ANIMALS; ATRIAL FIBRILLATION; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; EVIDENCE-BASED MEDICINE; HUMANS; ION CHANNEL GATING; PIPERAZINES; TREATMENT OUTCOME;

EID: 78649508017     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.2010.535517     Document Type: Review

References (58)

1. Rosenthal L, McManus DD. Atrial fibrillation. emedicine, Omaha, NE; 2010. Available from: http://emedicine. medscape.com/article/151066-print [Last accessed 31 October 2010]
2. Nattel S. New ideas about atrial fibrillation 50 years on. Nature 2002;415:219-26
3. Burashnikov A, Antzelevitch C. New developments in atrial anti-arrhythmic drug therapy. Nat Rev Cardiol 2010;7:139-48
4. Nattel S. Basic electrophysiology of the pulmonary veins and their role in atrial fibrillation: precipitators, perpuators, and perplexers. J Cardiovasc Electrophysiol 2003;14:1372-5
5. Fogoros RN. Ablation - a cure of atrial fibrillation? Not quite, but we're getting closer, New York, NY: About.com Heart Health Center, 2005. Available from: http://heartdisease.about.com/cs/ arrhythmias/a/ablateafib.htm [Last accessed 31 October 2010]
6. DrugBank: Showing Ranolazine (DB00243). Alberta, Canada, DrugBank, 2008. Available from: http://www. drugbank.ca/drugs/DB00243 [Last accessed 31 October 2010]
7. Wishart DS, Knox C, Guo AC, et al. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res 2008;36(Database issue): D901-9
8. Nash DT, Nash SD. Ranolazine for chronic stable angina. Lancet 2008;372:1335-41
9. Lee L, Horowitz J, Frenneaux M. Metabolic manipulation in ischaemic heart disease, a novel approach to treatment. Eur Heart J 2004;25:634-41
10. Anderson JR, Nawarskas JJ. Ranolazine. A metabolic modulator for the treatment of chronic stable angina. Cardiol Rev 2005;13:202-10
11. Tian L, Jiang J, Huang Y, et al. Sensitive quantification of ranolazine in human plasma by liquid chromatography - tandem mass spectrometry with positive electrospay ionization. J Chromatogr B Analyt Technol Biomed Life Sci 2007;846:346-50
12. MacInnes A, Fairman DA, Binding P, et al. The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2003;93:e26-32
13. Antzelevitch C, Belardinelli L, Zygmunt AC, et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 2004;110:904-10
14. Zerumsky K, McBride BF. Ranolazine in the management of chronic stable angina. Am J Health Syst Pharm 2006;63:2331-8
15. Belardinelli L, Shryock JC, Fraser H. Inhibition of the late sodium current as a potential cardioprotective principle: effect of the late sodium current inhibitor ranolazine. Heart 2006;92(Suppl IV):iv6-14
16. Zaza A, Belardinelli L, Shryock JC. Pathophysiology and pharmacology of the cardiac "late sodium current". Pharmacol Ther 2008;119:326-39
17. DrugBank: Showing Lignocaine (DB00282). Alberta, Canada, DrugBank, 2008. Available from: http://www. drugbank.ca/drugs/DB00281 [Last accessed 31 October 2010]
18. Wishart DS, Knox C, Guo AC, et al. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res 2008;36(Database issue):D901-9
19. Fredj S, Sampson KJ, Liu H, Kass RS. Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action. Br J Pharmacol 2006;148:16-24
20. Schram G, Zhang L, Derakhchan K, et al. Ranolazine: ion-channel-blocking actions and in vivo electrophysiological effects. Br J Pharmacol 2004;142:1300-8
21. Song Y, Shryock JC, Wu L, Belardinelli L. Antagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in guinea pig ventricular myocytes. J Cardiovasc Pharmacol 2004;44:192-9
22. Undrovinas AI, Belardinelli L, Undrovinas NA, Sabbah HN. Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current. J Cardiovasc Electrophysiol 2006;17(Suppl 1):S169-77
23. Rajamani S, Shryock JC, Belardinelli L. Block of tetrodotoxin-sensitive, Na(V)1.7 and tetrodotoxin-resistant, Na(V)1.8, Na+ channels by ranolazine. Channels (Austin) 2008;2:449-60
24. Wang GK, Calderon J, Wang SY. State- and use-dependent block of muscle Nav1.4 and neuronal Nav1.7 voltage-gated Na+ channel isoforms by ranolazine. Mol Pharmacol 2008;73:940-8
25. Rajamani S, El-Bizri N, Shryock JC, et al. Use-dependent block of cardiac late Na+ current by ranolazine. Heart Rhythm 2009;6:1625-31
26. Allen TJ, Chapman RA. Effects of ranolazine on L-type calcium channel currents in guinea-pig single ventricular myocytes. Br J Pharmacol 1996;118:249-54
27. Antzelevitch C, Belardinelli L, Wu L, et al. Electrophysiologic properties and antiarrhythmic actions of a novel antianginal agent. J Cardiovasc Pharmacol Ther 2004;9(Suppl 1):S65-83
28. Rajamani S, Shryock JC, Belardinelli L. Rapid kinetic interactions of ranolazine with HERG K+ current. J Cardiovasc Pharmacol 2008;51:581-9
29. Wu L, Rajamani S, Li H, et al. Reduction of repolarization reserve unmasks the proarrhythmic role of endogenous late Na+ current in the heart. Am J Physiol Heart Circ Physiol 2009;297:H1048-1057
30. Hancox JC, McPate MJ, El Harchi A, Zhang YH. The hERG potassium channel and hERG screening for drug-induced torsades de pointes. Pharmacol Ther 2008;119:118-32
31. Fedida D, Orth PM, Hesketh JC, Ezrin AM. The role of late I and antiarrhythmic drugs in EAD formation and termination in Purkinje fibers. J Cardiovasc Electrophysiol 2006;17(Suppl 1):S71-8
32. Burashnikov A, Di Diego JM, Zygmunt AC, et al. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation 2007;116:1449-57
33. Burashnikov A, Di Diego JM, Zygmunt AC, et al. Atrial-selective sodium channel block as a strategy for suppression of atrial fibrillation. Ann N Y Acad Sci 2008;1123:105-12
34. Sicouri S, Glass A, Belardinelli L, Antzelevitch C. Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations. Heart Rhythm 2008;5:1019-26
35. Kumar K, Nearing BD, Carvas M, et al. Ranolazine exerts potent effects on atrial electrical properties and abbreviates atrial fibrillation duration in the intact porcine heart. J Cardiovasc Electrophysiol 2009;20:796-802
36. Carvas M, Nascimento BC, Acar M, et al. Intrapericardial ranolazine prolongs atrial refractory period and markedly reduces atrial fibrillation inducibility in the intact porcine heart. J Cardiovasc Pharmacol 2010;55:286-91
37. Song Y, Shryock JC, Belardinelli L. A slowly inactivating sodium current contributes to spontaneous diastolic depolarization of atrial myocyctes. Am J Physiol Heart Circ Physiol 2009;297:H1254-62
38. Sicouri S, Burashnikov A, Belardinelli L, Antzelevitch C. Synergistic electrophysiologic and antiarrhythmic effects of the combination of ranolazine and chronic amiodarone in canine atria. Circ Arrhythm Electrophysiol 2010;3:88-95
39. Antzelevitch C, Burashnikov A. Atrial-selective sodium channel block as a novel strategy for the management of atrial fibrillation. J Electrocardiol 2009;42:543-8
40. Sossalla S, Kallmeyer B, Wagner S, et al. Altered Na+ currents in atrial fibrillation effects of ranolazine on arrhythmias and contractility in human atrial myocardium. J Am Coll Cardiol 2010;55:2330-42
41. Schotten U, Verheule S, Kerfant BG, Greiser M. Enhanced late Na+ currents in atrial fibrillation new drug target or just an epiphenomenon? J Am Coll Cardiol 2010;55:2343-5
42. Chaitman BR, Skettino SL, Parker JO, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 2004;43:1375-82
43. Chaitman BR, Pepine CJ, Parker JO, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina - a randomized controlled trial. JAMA 2004;291:309-16
44. Stone PH, Gratsiansky NA, Blokhin A, et al. Antianginal efficacy of ranolazine when added to treatment with amlodipine. The ERICA (Efficacy of Ranolazine in Chronic Angina) Trial. J Am Coll Cardiol 2006;48:566-75
45. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA 2007;297:1775-83
46. Scirica BM, Morrow DA, Hod H, et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndrome thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation 2007;116:1647-52
47. Murdock DK, Kersten M, Kaliebe J, Larrain G. The use of oral ranolazine to convert new or paroxysmal atrial fibrillation: a review of experience with implications for possible "pill in the pocket" approach to atrial fibrillation. Indian Pacing Electrophysiol J 2009;9:260-7
48. Goldstein RN, Khrestian C, Carlsson L, Waldo AL. AZD7009; a new antiarrhythmic drug with predominant effects on the atria effectively terminates and prevents reinduction of atrial fibrillation and flutter in the sterile pericarditis model. J Cardiovasc Electrophysiol 2004;15:1444-50
49. Wu Y, Carlsson L, Liu T, et al. Assessment of the proarrhythmic potential of the novel antiarrhythmic agent AZD7009 and dofetilide in experimental models of torsades de pointes. J Cardiovasc Electrophysiol 2005;16:898-904
50. Lofberg L, Jacobsen I, Carlsson L. Electrophysiological and antiarrhythmic effects of the novel antiarrhythmic agent AZD7009: a comparison with azilimide and AVE0118 in the acutely dilated right atrium of the rabbit in vitro. Europace 2006;8:549-57
51. Persson F, Carlsson L, Duker G, Jacobson I. Blocking characteristics of hERG, hNav1.5, and hKvLQT1/hminK after administration of the novel anti-arrhythmic compound AZD7009. J Cardiovasc Electrophysiol 2005;16:329-41
52. Persson F, Carlsson L, Duker G, Jacobson I. Blocking characteristics of hKv1.5 and hKv4.3/hKChIP2.2 after administration of the novel antiarrhythmic compound AZD7009. J Cardiovasc Pharmacol 2005;46:7-17
53. Crijns HV, Van Gelder IC, Walfridsson H, et al. Safe and effective conversion of persistent atrial fibrillation to sinus rhythm by intravenous AZD7009. Heart Rhythm 2006;3:1321-31
54. Geller JC, Egstrup K, Kulakowski P, et al. Rapid conversion of persistent atrial fibrillation to sinus rhythm by intravenous AZD7009. J Clin Pharmacol 2009;49:312-22
55. Baczko I, El-Reyani NE, Farkas A, et al. Antiarrhythmic and electrophysiological effects of GYKI-16638, a novel N-(phenoxyalkyl)-N- phenylalkyamine, in rabbits. Eur J Pharmacol 2000;404:181-90
56. Opincariu M, Varro A, Lost N, et al. The cellular electrophysiologic effect of a new amiodarone like antiarrhythmic drug GYKI 16638 in undiseased human ventricular muscle: comparison with sotalol and mexiletine. Curr Med Chem 2002;9:41-6
57. Matyrus P, Varga I, Rettegi T, et al. Novel antiarrhythmic compounds with combine IB and class III mode of action. Curr Med Chem 2004;11:61-9
58. Burashnikov A, Sicouri S, Di Diego JM, et al. Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation. J Am Coll Cardiol 2010;56:1216-24